Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.2K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

8.1K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sarcopenia modifies the survival benefit of triple therapy versus TACE alone in elderly patients with unresectable hepatocellular carcinoma: A multicenter retrospective cohort study.

Scientific reports·2026
Same author

S-adenosylhomocysteine hydrolase-like protein 1 deficiency resulted in stronger inflammation reaction in acute pancreatitis.

Journal of gastroenterology·2026
Same author

Core transcriptional regulatory circuitry molecule ZNF217 promotes AML cell proliferation by up-regulating MYB.

International journal of biological sciences·2025
Same author

Integrated UPLC-ESI-MS/MS, network pharmacology, and transcriptomics to reveal the material basis and mechanism of Schisandra chinensis Fruit Mixture against diabetic nephropathy.

Frontiers in immunology·2025
Same author

IRF1 is a core transcriptional regulatory circuitry member promoting AML progression by regulating lipid metabolism.

Experimental hematology & oncology·2025
Same author

Controlled Release of Cold Atmospheric Plasma by Gelatin Scaffold Enhances Wound Healing via Macrophage Modulation.

ACS applied materials & interfaces·2025

Related Experiment Video

Updated: Jan 6, 2026

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

1.9K

CERKL Reduced PI3P/Autophagy to Promote Pancreatic Cancer.

Wenying Zeng1,2, Yinhui Yang1, Wanlian Li1

  • 1Guangxi Key Laboratory of Molecular Medicine in Liver Injury and Repair, Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, People's Republic of China.

Cancer Medicine
|November 25, 2025
PubMed
Summary

Ceramide Kinase Like (CERKL) is upregulated in pancreatic cancer (PC), promoting tumor cell migration and invasion. A specific mutation (L296V) enhances this effect, highlighting a potential therapeutic target.

Keywords:
CERKLTrim21autophagypancreatic cancerphosphatidyl inositol

More Related Videos

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K

Related Experiment Videos

Last Updated: Jan 6, 2026

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence
08:07

Evaluating Autophagy Levels in Two Different Pancreatic Cell Models Using LC3 Immunofluorescence

Published on: April 28, 2023

1.9K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

1.3K
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

1.4K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Pancreatic cancer (PC) is a significant gastrointestinal malignancy with poorly understood molecular drivers.
  • The role of the Ceramide Kinase Like (CERKL) gene in PC pathogenesis remains largely unelucidated.

Purpose of the Study:

  • To investigate the expression, function, and regulatory mechanisms of CERKL in pancreatic cancer.
  • To identify potential mutations in CERKL and their impact on PC progression.

Main Methods:

  • Bioinformatic analysis of online databases for CERKL mRNA expression and mutations in PC.
  • In vitro and in vivo studies using cell lines and mouse models to assess CERKL function.
  • Investigation of CERKL regulation by E3 ligases and its impact on lipid metabolism and autophagy.
  • Analysis of clinical samples for CERKL expression and mutation status.

Main Results:

  • CERKL mRNA and protein levels are significantly elevated in PC tissues.
  • CERKL promotes PC cell migration and invasion both in vitro and in vivo.
  • A novel L296V mutation in CERKL was identified in PC patients, which further enhances migratory and invasive capabilities.
  • TRIM21, an E3 ligase, negatively regulates CERKL protein levels and stability; the L296V mutation impairs this interaction.
  • CERKL influences phosphatidylinositol levels and regulates autophagy, with the L296V mutation exhibiting a stronger effect.
  • Autophagy modulation can impact CERKL-driven metastasis.

Conclusions:

  • A novel TRIM21/CERKL/autophagy pathway is implicated in pancreatic cancer progression.
  • CERKL, particularly its L296V mutant form, acts as a tumor promoter in PC.
  • Targeting CERKL or its regulatory pathways may offer therapeutic strategies for pancreatic cancer.